AMLX
Amylyx Pharmaceuticals, Inc.
$38.66
-2.52%
2026-08-21
About Amylyx Pharmaceuticals, Inc.
Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Key Fundamentals
Forward P/E
-15.72
EPS (TTM)
$-1.41
ROE
-74.7%
Profit Margin
0.0%
Debt/Equity
2.20
Price/Book
10.07
Beta
-0.20
Market Cap
$2.41B
Avg Volume (10D)
1.9M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$41.13
60D Low
$12.62
Avg Volume
2.4M
Latest Close
$38.66
Get breakout alerts for AMLX
Sign up for Breakout Scanner to receive daily notifications when AMLX triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial.
Amylyx Pharmaceuticals, Inc. (AMLX) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors AMLX daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. AMLX operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry. Data is provided for informational purposes only and does not constitute financial advice.